San Diego, CA -- (SBWIRE) -- 08/27/2014 -- An investigation on behalf of investors, who currently hold shares of InterMune Inc (NASDAQ:ITMN), was announced concerning whether the takeover of InterMune Inc by Roche at $74.00 per share is unfair to NASDAQ:ITMN stockholders.

Investors who purchased shares of InterMune Inc (NASDAQ:ITMN) and currently hold any of those NASDAQ:ITMN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of InterMune Inc breached their fiduciary duties owed to NASDAQ:ITMN investors in connection with the proposed acquisition.

On August 24, 2014, Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) announced they have entered into a merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction.

However, the investigation concerns whether the offer is unfair to NASDAQ:ITMN stockholders. More specifically, the investigation concerns whether the InterMune Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

InterMune Inc reported that its annual Total Revenue rose from $5.41 million in 2011 to $70.34 million in 2013.

Shares of InterMune Inc (NASDAQ:ITMN) grew from $7.37 per share in August 2013 to as high as $54.94 per share on August 20, 2014.

On August 25, 2014 NASDAQ:ITMN shares closed at $72.85 per share

Those who are current investors in InterMune Inc (NASDAQ:ITMN) shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com